The COST action EURO-VALDI-NET aims to create a pan-European multidisciplinary co-operative network of stakeholders, bringing together scientists, clinicians, industry partners, and patients associations, to address the vascular liver diseases problems. Through the creation of shared data registries on main relevant basic and clinical aspects, conference calls, meetings, workshops, as well as training schools, this Action will coordinate efforts aiming at advancing the understanding of vascular liver diseases to translate basic
research and preclinical findings into clinical practice.
For this purpose, EURO-VALDI-NET will be organized into 6 working groups:
1- Epidemiology, comprehensive clinical characterization, harmonization of biosamples collection, Risk stratification, clinical trial design in VLD
2- Comprehensive histological characterization for PSVD
3- Comprehensive radiological characterization of vascular liver diseases
4- Development of screening tools and diagnostic biomarkers for PSVD
5- Health-related quality of life (HRQoL) and patient reported outcomes (PRO) in VLD
6- Preclinical models of vascular liver diseases, identification of therapeutic targets and development of new therapeutic approaches for VLD
Please find more information there:
The COST action EURO-VALDI-NET aims to create a pan-European multidisciplinary co-operative network of stakeholders, bringing together scientists, clinicians, industry partners, and patients associations, to address the vascular liver diseases problems. Through the creation of shared data registries on main relevant basic and clinical aspects, conference calls, meetings, workshops, as well as training schools, this Action will coordinate efforts aiming at advancing the understanding of vascular liver diseases to translate basic
research and preclinical findings into clinical practice. For this purpose, EURO-VALDI-NET will be organized into 6 working groups:
1- Epidemiology, comprehensive clinical characterization, harmonization of biosamples collection, Risk stratification, clinical trial design in VLD
2- Comprehensive histological characterization for PSVD
3- Comprehensive radiological characterization of vascular liver diseases
4- Development of screening tools and diagnostic biomarkers for PSVD
5- Health-related quality of life (HRQoL) and patient reported outcomes (PRO) in VLD
6- Preclinical models of vascular liver diseases, identification of therapeutic targets and development of new therapeutic approaches for VLD
Please find more information there: https://www.cost.eu/actions/CA23146/